Emyria Opens Empax Centre to Advance Mental Health Care
Released
Released
Announcement PDF
Delivering & developing new treatments for mental
health & neurological conditions
ASX Announcement | 10 April 2024
Emyria Launches New Clinic - The Empax Centre - Dedicated to
Advanced Mental Health Treatment and Research
HIGHLIGHTS
Emyria has opened a new, state-of-the-art facility - The Empax Centre - and expanded its
clinical service capacity dedicated to the delivery and development of new treatments for
mental health such as MDMA-assisted therapy (MDMA-AT) for PTSD.
Led by some of Australia's first authorised MDMA-AT prescribers 1, 2 , the Empax Centre
features advanced technology for superior patient care and data-driven research.
Emyria’s first Empax Centre is aiming at achieving operational profitability by H2 2024 with
potential for national and global scalability via further site expansion.
Empax Centre to initially target critical gaps in care for resistant PTSD, with a strategy to
expand therapeutic offerings using the same foundational infrastructure.
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on delivering and
developing new treatments for mental health and select neurological conditions, is proud to
announce the opening of the Empax Centre, a state-of-the-art facility dedicated to the
delivery and development of new treatments for mental health such as psychedelic-assisted
therapies. This purpose-built centre combines patient-centred design and cutting-edge
technology and increases Emyria’s clinical service capacity to support the treatment and
research of complex mental health conditions such as Post-Traumatic Stress Disorder (PTSD).
Named to reflect empathy and homage to its founding entities, Emyria and The Pax Centre,
the Empax Centre is dedicated to the delivery and Real-World evaluation of new mental
health treatments such as MDMA-assisted therapy for individuals with difficult-to-treat PTSD.
The Empax Centre reflects the Company’s commitment to addressing unmet needs in
mental health and, at full capacity, is expected to substantially increase the Company’s care
delivery and research revenues as well as directly support the Company’s innovation pipeline
of new care models and proprietary drug therapies.
Market Potential - Unmet Needs in PTSD Treatment:
The Empax Centre's founding mission is to serve a significant yet underserved population —
those grappling with resistant forms of PTSD, including many first responders. With an
estimated 1 million Australians living with PTSD 3, and a substantial portion not responding to
standard treatments, the Empax Centre is uniquely positioned to address this gap by
supporting new treatment research such as the recently announced study with charity
Reach Wellness, to evaluate MDMA-AT for first responders with PTSD 4. The Empax Centre
will be the trial location for the Reach Wellness study.
Emyria ASX Announcement | 10 Apr 2024
1
Select features
Multiple, dedicated
therapy rooms
Discrete AV and
data capture
Full sound-proofing
for privacy
In-room & headphone audio;
AI-generated music
Emyria ASX Announcement | 10 Apr 2024
1
Innovation and Excellence in Care
Led by pioneers in the field, including two of Australia’s first authorised prescribers of
MDMA-assisted therapy, the Empax Centre has a supporting team of over 14 clinicians
specially trained in psychedelic-assisted therapy. The facility is therefore designed to support
the unique requirements of these treatments including dedicated spaces to ensure patient
comfort and safety over extended sessions, complemented by advanced audio-visual (AV)
monitoring and an AI-generated music system for an unparalleled therapeutic experience.
Commitment to Research and Evidence-Based Innovation
The Centre is expected to become a centre of excellence for care delivery and research and
development and a core focus of the Empax Centre is to capture robust clinical evidence
while providing unparalleled patient care. This data-driven approach supports Emyria's
long-term innovation agenda which involves actively developing new and improved care
models as well as novel drug treatments inspired by MDMA 5.
Commercialisation Strategy
The Empax Centre is expected to support a range of new therapies and research in addition
to MDMA-AT, such as psilocybin-assisted therapy for treatment-resistant depression.
Furthermore, the Centre has been designed as a blueprint for scalable mental health
treatment nationwide and globally. Consequently, the Empax Centre is expected to support
multiple revenue streams from both direct patient care and sponsored clinical research with
the first Centre anticipated to reach operating break-even by the second half of 2024.
Additional centres are in early stages of planning.
There are currently no products containing psilocybin or MDMA included in the Australian
Register of Therapeutic Goods (ARTG) that have been evaluated by the TGA for safety, quality
and efficacy. However, there is now sufficient evidence that psilocybin and MDMA will
potentially be effective in the treatment of treatment-resistant depression (TRD) and PTSD,
respectively, for certain patients. In particular, clinical trials have shown promise when they
are used in combination with psychotherapy in strictly controlled medical settings.
Long-term Innovation Pipeline
As part of Emyria’s unique strategy, the Company utilises revenues and data generated from
its suite of clinical services to support proprietary innovation efforts comprising new care
models and novel drug development. The Company is currently advancing an ambitious
MDMA analogue development program with global partners, the University of Western
Australia (UWA) and the National Institute of Health (NIH) in the USA.5 The Company has
also been given a clear search report from the international patent examiner 7, indicating
the novelty and potential patentability of a massive library of novel MDMA analogues with
the potential to become a new treatments for PTSD.
Dr. Michael Winlo, CEO: "The Empax Centre demonstrates Emyria’s commitment to lead
the way in mental health innovation within the regulatory frameworks set by the TGA.
Our extensive research and development efforts, particularly in MDMA-assisted therapy for
PTSD, have shaped our strategic approach towards scalability and profitability - essential
for the widespread adoption and success of these innovative treatments.
This new facility not only signifies our commitment to improving mental health care but
also highlights our firm belief in the transformative potential of our treatments.”
Emyria ASX Announcement | 10 Apr 2024
1
Risks associated with the use of Psilocybin, MDMA and Ketamine 6
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best
placed to assess the suitability of a new medication against a patient’s individual
circumstances and medical history before proceeding. Adverse effects of psilocybin can
include temporary increase in blood pressure and a raised heart rate. Adverse effects of
MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in
some rare cases it can cause loss of consciousness or trigger seizures. Other side effects
include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache,
sweating and muscle/joint stiffness. These effects of psilocybin and MDMA are unlikely at
low doses in the treatment regimens used in psychedelic-assisted psychotherapy while
appropriately managed in a controlled environment with direct medical supervision.
Ketamine has potential to cause acute physical, psychiatric, psychotomimetic and cognitive
side effects following a single dose and cumulative side effects resulting from repeated
dosing. The majority of studies of ketamine in depression have examined side effects only
acutely and after a single dose, with limited studies examining safety in repeated doses.
Acute physical adverse effects of ketamine include hypertension, sedation, nausea or
vomiting, headache, poor coordination, poor concentration, dizziness, blurred vision, and
restlessness. The potential of ketamine to induce acute hypertension, lower urinary tract
dysfunction and interstitial cystitis, and alter hepatic function, and noting that ketamine is
metabolised by the liver, warrant screening for relevant pre-existing conditions.
References:
1.
2.
3.
4.
5.
6.
See ASX release 10 January 2024
See ASX release 05 April 2024
https://www.phoenixaustralia.org/news/ptsd-awareness-day-2022/
See ASX release 03 April 2024
See ASX release 28 February 2024
https://www.ranzcp.org/getmedia/75baa529-2b71-419f-993a-2ff64ede50fe/cm-use-of-ketaminein-psychiatric-practice.pdf
This release has been approved by the Board of Emyria.
For further information, investment opportunities, or more about our approach to
mental health treatment, please contact:
Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com
Emyria ASX Announcement | 10 Apr 2024
Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital
Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au
1
emyria.com
Emyria Limited is focused on developing and delivering new treatments for mental health and select
neurological conditions through through an integrated model of direct clinical services and drug
development:
generates
Emyria Healthcare: Evidence-based treatment for patients not finding relief from
conventional care while also helping evaluate emerging new therapies like
MDMA-assisted therapy for PTSD 1
Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients
and used to improve Emyria’s unique therapy and drug development programs.
informs
Emyria’s Pipeline: One of the world's largest libraries of unique MDMA-like
compounds developed in partnership with the University of Western Australia seeking
new psychedelic-assisted therapies and treatments for neurological diseases as well as
highly potent dose forms of Ultra-Pure CBD seeking registration for a range of mental
health and neuroscience indications.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates
by asking questions and comments, which our team can respond to where possible.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release
about future expectations, plans and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various important
factors, including: the Company’s ability to successfully develop its product candidates and timely
complete its planned clinical programs and the Company’s ability to obtain marketing approvals for
its product candidates. In addition, the forward-looking statements included in this press release
represents the Company’s views as of the date hereof. The Company anticipates that subsequent
events and developments will cause the Company’s views to change. However, while the Company
may elect to update these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Emyria ASX Announcement | 10 Apr 2024
1
Share your feedback
Discover